Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 09/28 09:54:18 pm
55.126 USD   -1.10%
09/28 GLOBAL DRUGS FO : Janssen, Celgene, Bristol-Myers Squibb, Grunenthal..
09/28 RAYTHEON : Adds Harman CEO Dinesh Paliwal to Board of Directors
09/27 BRISTOL MYERS S : and Nektar Therapeutics Announce Oncology Clinical..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 07:01pm CEST
   By Peter Loftus 
   Of  
 

Drug maker Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas.

Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries."

The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing.

Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA.

U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement.

Last year, Johnson & Johnson (>> Johnson & Johnson) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein.

Other drug makers--including Pfizer Inc. (>> Pfizer Inc.), Merck & Co. (>> Merck & Co., Inc.) and Eli Lilly & Co. (>> Eli Lilly & Co.)--also have been the subjects of federal inquiries regarding the FCPA.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB CO
09/28 GLOBAL DRUGS FOR TREATMENT OF MULTIP : Janssen, Celgene, Bristol-Myers Squibb, G..
09/28 RAYTHEON : Adds Harman CEO Dinesh Paliwal to Board of Directors
09/27 BRISTOL MYERS SQUIBB : and Nektar Therapeutics Announce Oncology Clinical Collab..
09/22 BRISTOL MYERS SQUIBB : to Take Part in Leerink Partners Immuno-Oncology Roundtab..
09/22 BRISTOL MYERS SQUIBB : FDAnews Announces -- Future-Proofing Your Clinical Trial ..
09/20 BRISTOL MYERS SQUIBB : Awards First “Golden Tickets” for LabCentral ..
09/20 BRISTOL MYERS SQUIBB : European Medicines Agency Validates Bristol-Myers Squibb&..
09/20 BRISTOL MYERS SQUIBB : Nippon Life Insurance Co Lowers stake in Bristol-Myers Sq..
09/15 BRISTOL MYERS SQUIBB : An Application for the Trademark "TOGEVDO" Has Been Filed..
09/15 BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Further Understanding o..
More news
Sector news : Pharmaceuticals - NEC
09/28DJINTRA CELLULAR THERAPIES : Shares Plunge After Disappointing Drug Trial Results
09/28DJGLAXOSMITHKLINE : to Sell Remaining 6.2% Stake in Aspen Pharmacare
09/28 Monsanto ally Novozymes sees opportunity, risk in Bayer merger
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/28 BEST NEAR-TERM PRICE GAINS AHEAD FOR : Big Pharma Stocks
09/28 Market Is Rewarding High Growth Stocks - Cramer's Mad Money (9/27/16)
09/27 Bristol-Myers and Nektar Therapeutics to explore potential of Opdivo and NKTR..
09/26 BUY ABBVIE INCORPORATED : Its Frustration Is Your Long-Term Gain
09/22 Biotech ETF IBB Could Get A Boost From A Potential Gilead Merger Or Acquisiti..
Advertisement
Financials ($)
Sales 2016 18 872 M
EBIT 2016 4 999 M
Net income 2016 4 369 M
Debt 2016 1 166 M
Yield 2016 2,78%
P/E ratio 2016 21,56
P/E ratio 2017 18,65
EV / Sales 2016 5,00x
EV / Sales 2017 4,54x
Capitalization 93 134 M
More Financials
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 67,4 $
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-18.97%92 699
JOHNSON & JOHNSON16.06%322 232
ROCHE HOLDING LTD.-12.41%215 081
NOVARTIS AG-10.14%211 231
PFIZER INC.4.80%204 049
MERCK & CO., INC.18.46%171 858
More Results